Loading...

BSX BOSTON SCIENTIFIC CORP US FDA Inspections 8-K Filing

BSTN

BSX

BOSTON SCIENTIFIC CORP

(BSX)

2024 8-K

Show Summary

Show Summary

Product Discontinuation

Financial Statements

Senior Notes Offering

Board Departure

Financial Results

Court Settlement

Executive Compensation

Acquisition Completed

Clinical Trial Resumption

Q3 Financial Results

Appointment of Director

Earnings Reports

Appointment of Director and...

By-Laws Amendment

Financial Results Announcement

Underwriting Agreement for ...

Appointment of Officers

Financial Results Announcement

Merger Agreement

Acquisition of Axonics, Inc.

Departure of Directors and ...

Earnings Reports

Earnings Reports

Appointment of Directors

Conversion of Preferred Stock

Annual Meeting of Stockholders

Financial Results Announcement

External Links:

Boston Scientific Corporation is resuming the AVANT GUARD clinical trial for drug-naive patients with persistent atrial fibrillation after a review by the study's data monitoring committee.

AI Assistant

BOSTON SCIENTIFIC CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.